A Phase 3 interventional study of Tylex in Alzheimer Disease, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Xuanwu Hospital, Beijing · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing — 19 open to participants now, 20 under way, 1 of them phase 3. Alzheimer Disease · Xuanwu Hospital, Beijing.
Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 8 that started in 2025, is the only one in phase 3, reaches primary completion later than 7 of the 19 other live ones, and was the 21st registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →19 of the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 50+
Xuanwu Hospital, Beijing · Sites in China
Ages 50+ · Healthy volunteers
Xuanwu Hospital, Beijing · Sites in China
Ages 50–90
Xuanwu Hospital, Beijing · Sites in China
Ages 60–80
Xuanwu Hospital, Beijing · Sites in China
Ages 50–90
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 1 · Phase 3 1
First in 2016; this study’s year is marked. 8 started in 2025.
This study's planned enrollment of 10 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 40 across the 19 interventional studies, 2,300 across the 7 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
5 of the studies in Alzheimer Disease by Xuanwu Hospital, Beijing that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07323914Phase 3Xuanwu Hospital, BeijingClinical Analgesic Management in Dementia | 2027-01-01 |
| NCT07323927Xuanwu Hospital, BeijingInvestigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease | 2027-01-01 |
| NCT07208734Xuanwu Hospital, BeijingPersonalized Brain Stimulation for Cognitive Impairment in Older Adults | 2027-06-01 |
| NCT06607900Xuanwu Hospital, BeijinghUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases | 2027-08-31 |
| NCT07230158Xuanwu Hospital, BeijingTranscranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II) | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the efficacy and safety of oxycodone in managing moderate to severe pain in patients with Alzheimer's disease. The trial will be conducted at Xuanwu Hospital, Capital Medical University, and will enroll 10 eligible participants. Participants will receive oxycodone/acetaminophen (5 mg/325 mg) once daily for 12 weeks. The treatment will follow international guidelines, with dosages adjusted based on the patient's baseline pain levels and individual needs. Dosages will be adjusted based on baseline pain levels and patient needs, following international guidelines. Efficacy and adverse events will be assessed at baseline, week 6, week 12, and at a 12-week post-treatment follow-up. The primary outcome is change in VAS pain scores; secondary outcomes include PAINAD, SF-36, functional ability, and safety profiles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tylex
Tylenol (compound oxycodone/acetaminophen) is a non-narcotic analgesic that combines a lower dose of oxycodone (5 mg) with acetaminophen (325 mg). Compared to OxyContin, it provides milder opioid potency and utilizes a synergistic mechanism to achieve pain control with reduced risk of opioid-related side effects.
Pain Assessment in Advanced Dementia Scale (PAINAD)
Time frame: baseline, 6 weeks, 12 weeks, 24 weeks.
Changes from baseline of exploratory blood biomarkers
Description: Exploratory blood biomarkers related to astrocyte-neuron interactions will be assessed using the SomaScan 11k platform. These include glial fibrillary acidic protein (GFAP), S100B, YKL-40, β-synuclein, neuregulin 1, GluN2A, and neurogranin.
Time frame: baseline; 12 weeks.
Mobilization-Observation-Behavior-Intensity-Dementia Pain Scale, version 2 (MOBID-2)
Time frame: baseline, 6 weeks, 12 weeks, 24 weeks.
Change from Baseline in Brain Amyloid Plaque Deposition as measured by PET Scan
Time frame: baseline; 12 weeks.
Change from baseline on the Neuropaychiatic Inventory (NPI)
Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.
Change from baseline on the Alzheimer's Disease Cooperative study-Activities of Daily Living Scale(ADCS-ADL)
Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.
Change from baseline on the Alzheimer's Disease Cooperative study-clinical global impression of change scale(ADCS-CGIC)
Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.
Change from baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.
Change from baseline on the Mini Mental state Examination (MMSE) score
Time frame: baseline; 6 weeks; 12 weeks; 24 weeks.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.
Of 101 phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 73. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.